Soy diet for nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials.
Study Goal
The researchers aimed to determine the influence of a soy diet versus placebo on non-alcoholic fatty liver disease, including its effects on alanine aminotransferase levels.
Results Summary
The study found that a soy diet had no substantial impact on alanine aminotransferase levels (SMD = -0.01; 95% CI = -0.61 to 0.60; P = 0.98). The diet was associated with reduced insulin resistance and malondialdehyde but showed no significant effects on other metabolic markers.
Population
Patients with non-alcoholic fatty liver disease.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
soy diet | decrease | HOMA-IR | patients with nonalcoholic fatty liver disease | SMD = -0.42; 95% CI = -0.76 to -0.08; P = .01 | significantly reduced | #1 |
soy diet | increase | insulin | patients with nonalcoholic fatty liver disease | SMD = -0.64; 95% CI = -0.98 to -0.30; P = .0002 | increased | #2 |
soy diet | decrease | malondialdehyde | patients with nonalcoholic fatty liver disease | SMD = -0.43; 95% CI = -0.74 to -0.13; P = .005 | decreased | #3 |
soy diet | no change | body mass index | patients with nonalcoholic fatty liver disease | SMD = 0.17; 95% CI = -0.20 to 0.53; P = .37 | demonstrated no substantial impact on | #4 |
soy diet | no change | alanine aminotransferase | patients with nonalcoholic fatty liver disease | SMD = -0.01; 95% CI = -0.61 to 0.60; P = .98 | demonstrated no substantial impact on | #5 |
soy diet | no change | aspartate-aminotransferase | patients with nonalcoholic fatty liver disease | SMD = 0.01; 95% CI = -0.47 to 0.49; P = .97 | demonstrated no substantial impact on | #6 |
soy diet | no change | total cholesterol | patients with nonalcoholic fatty liver disease | SMD = 0.05; 95% CI = -0.25 to 0.35; P = .73 | demonstrated no substantial impact on | #7 |
soy diet | no change | low density lipoprotein | patients with nonalcoholic fatty liver disease | SMD = 0; 95% CI = -0.30 to 0.30; P = .99 | demonstrated no substantial impact on | #8 |
soy diet | decrease | insulin resistance | patients with nonalcoholic fatty liver disease | - | may benefit to alleviate | #9 |
INTRODUCTION: The efficacy of soy diet for nonalcoholic fatty liver disease remains controversial. We conduct a systematic review and meta-analysis to explore the influence of soy diet vs placebo on the treatment of non-alcoholic fatty liver disease. METHODS: We search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through October 2020 for randomized controlled trials assessing the efficacy of soy diet vs placebo for nonalcoholic fatty liver disease. This meta-analysis is performed using the random-effect model. RESULTS: Five randomized controlled trials are included in the meta-analysis. Overall, compared with control group for nonalcoholic fatty liver disease, soy diet is associated with significantly reduced HOMA-IR (standard mean difference [SMD] = -0.42; 95% confidence interval [CI] = -0.76 to -0.08; P = .01), increased insulin (SMD = -0.64; 95% CI = -0.98 to -0.30; P = .0002) and decreased malondialdehyde (SMD = -0.43; 95% CI = -0.74 to -0.13; P = .005), but demonstrated no substantial impact on body mass index (SMD = 0.17; 95% CI = -0.20 to 0.53; P = .37), alanine aminotransferase (SMD = -0.01; 95% CI = -0.61 to 0.60; P = .98), aspartate-aminotransferase (SMD = 0.01; 95% CI = -0.47 to 0.49; P = .97), total cholesterol (SMD = 0.05; 95% CI = -0.25 to 0.35; P = .73) or low density lipoprotein (SMD = 0; 95% CI = -0.30 to 0.30; P = .99). CONCLUSIONS: Soy diet may benefit to alleviate insulin resistance for nonalcoholic fatty liver disease.